PYXS MICVO posts 36% response rate and 6.2-month PFS in HNSCC
MICVO showed a 36% response rate and 6.2-month median PFS in 2L+ R/M HNSCC. Safety was manageable, with late-onset, reversible neuropathy. Phase 3 initiation is planned for mid-2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.